



Invitation to the

# First National Meeting on Fibromuscular Dysplasia

**Saturday 12<sup>th</sup> December 2015**  
**9h00-16h00**

**Auditoire Maisin**

(auditoires centraux de la Faculté de médecine de l'UCL)  
Avenue Emmanuel Mounier 51 - 1200 Brussels  
(see back cover for the map)

For information, please contact  
Prof. Alexandre Persu ([alexandre.persu@uclouvain.be](mailto:alexandre.persu@uclouvain.be))  
or Prof. Patricia Van der Niepen  
([Patricia.VanderNiepen@uzbrussel.be](mailto:Patricia.VanderNiepen@uzbrussel.be)).

This meeting is supported by  
the Belgian Hypertension Committee and  
the Rare Disease Institute of  
the Cliniques Universitaires Saint-Luc.

Accreditation in Ethics and Economy has been requested.

We are grateful to our sponsors


DAIICHI-SANKYO

BAYER


GENZYME



Daiichi-Sankyo



DAIICHI-SANKYO s.a.  
Mrs Sophie Allart  
Rue Fond Jean Pâques 5  
1348 Louvain-la-Neuve



Dear Colleagues from Belgium and abroad,

We are delighted to invite you to the first Belgian Meeting on Fibromuscular Dysplasia, a national meeting with a European and international faculty.

If you are nephrologist, cardiologist, neurologist, internist, paediatrician, radiologist, vascular surgeon, hypertension specialist or expert in vascular medicine, this meeting may be of interest for you.

Fibromuscular Dysplasia (FMD) needs to be revisited!

Did you know that:

- FMD lesions may be found in up to 5% of apparently healthy adults.
- In recent cohorts, the mean age at diagnosis is > 50 years, but FMD may also occur in children and elderly men.
- FMD is a systemic disease with frequent involvement of multiple vascular beds, including but not limited to renal and carotid arteries.
- FMD can be associated with spontaneous coronary artery dissection.
- FMD has an hereditary component and the first susceptibility genes are currently being identified.

Besides an update by some of the best experts of the disease from Belgium and abroad, this meeting will address important practical questions with pharmaco-economic and ethical relevance:

- When is it cost-effective to screen for FMD?
- Which is the best diagnostic algorithm?
- Should a patient with renal FMD be explored for cervical FMD and the reverse?
- When should angioplasty/surgery be considered?
- When is exploration of relatives justified?
- What should be done in case of incidental findings of FMD lesions?

Finally, the meeting will be an opportunity to present the BEL-FMD project, a Belgian multicentric cohort nested within a European initiative.

We look forward to meet you on 12<sup>th</sup> December 2015.

Prof. Patricia VAN DER NIEPEN  
Nephrology Department  
Universitair Ziekenhuis Brussel  
Vrije Universiteit Brussel

Prof. Alexandre PERSU  
Chairman of the ESH Working Group  
"Hypertension and the Kidney"  
Cardiology Department  
Cliniques Universitaires Saint-Luc  
Université Catholique de Louvain

## National meeting on Fibromuscular Dysplasia

### PROGRAM

|              |                                                                                                                                                    |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| 09h00-09h25  | <i>Welcome coffee</i>                                                                                                                              |
| 09h25-09h30  | <b>Introduction</b> (A. Persu, UCL)                                                                                                                |
| 09h30-10h00  | <b>The nephrologist's perspective</b><br>(P. Van der Niepen, VUB)<br>Discussants: P. de Leeuw (Maastricht) and<br>G. Wuerzner (Lausanne)           |
| 10h00-10h30  | <b>The neurologist's perspective</b> (E. Touzé, Caen)<br>Discussants: J. De Keyser (VUB) and<br>A. Peeters (UCL)                                   |
| 10h30-11h00  | <b>The cardiologist's perspective</b><br>(P. Motreff, Clermont-Ferrand)<br>Discussants: P. Chenu (UCL) and<br>S. Gevaert (UGent)                   |
| 11h00-11h30  | <i>Coffee Break</i>                                                                                                                                |
| 11h30-12h00  | <b>The patient's perspective</b><br>(P. Mace, FMDSA, Ohio)<br>Discussants: V. Godin and<br>M. Bouwmeester<br>(FMD groep Nederland)                 |
| 12h00-12h30  | <b>The European FMD consensus</b> (A.Persu, UCL)<br>Discussants: T. De Backer (UGent) and<br>J.-P. Lengelé (GHDC/UCL)                              |
| 12h30-14h00  | <i>Lunch</i>                                                                                                                                       |
| 14h00-14h30  | <b>Why FMD needs to be revisited:<br/>lessons from registries</b> (P-F. Plouin, Paris)<br>Discussants: K.Claes (KUL) and<br>J.C. Wautrecht (ULB)   |
| 14h30-14h45  | <b>BEL-FMD : a national project nested within<br/>a European initiative</b> (A. Persu, UCL)                                                        |
| 14h45-15h15  | <b>Strategies to unravel genes contributing<br/>to FMD</b> (X. Jeunemaitre, Paris)<br>Discussants: M. Vikkula (UCL) and<br>J. Wang (Shanghai)      |
| 15h15- 15h30 | <b>General discussion: towards a European registry<br/>and patient association</b><br>Chairmen: J.-M. Krzesinski (ULg) and<br>A. Morganti (Milano) |
| 15h30        | <b>Conclusion and take-home messages</b><br>(P. Van der Niepen, VUB)                                                                               |

Please send back the reply form to Mrs Sophie Allart (fax. 010/48 95 99) or confirm your presence by e-mail (sophie.allart@daichi-sankyo.be)

- Will attend meeting  
 Will not attend meeting

Name .....  
Title .....  
Address .....  
Phone ..... Fax .....  
Signature .....

Stamp

Please answer before 1<sup>st</sup> December 2015